Literature DB >> 24316062

Tumour co-expression of apelin and its receptor is the basis of an autocrine loop involved in the growth of colon adenocarcinomas.

François-Xavier Picault1, Carline Chaves-Almagro1, Fabrice Projetti2, Hervé Prats1, Bernard Masri1, Yves Audigier3.   

Abstract

Using a cancer profiling array, our laboratory has shown that apelin gene is up-regulated in half of colon adenocarcinomas. We have therefore postulated that apelin signalling might play a prominent role in the growth of colon tumours. We first confirmed by immunohistochemistry that apelin peptide is overexpressed in human colon adenomas and adenocarcinomas. We also observed a significant overexpression of apelin receptor (APJ) in adjacent sections. We then demonstrated that several colorectal cancer cell lines also expressed apelin and its receptor, the highest gene and peptide expression being detected in LoVo cells. In this cell line, the expression and functionality of apelin receptor were revealed by apelin-induced adenylyl cyclase inhibition and Akt phosphorylation. In addition, apelin clearly protected LoVo cells from apoptosis by inactivating a caspase-dependent pathway and decreasing the degradation of poly ADP ribose polymerase protein (PARP). Finally, treatment of these tumour cells by the (F13A)apelin13 receptor antagonist significantly reduced their proliferation rate. Altogether, these data suggest the existence of an autocrine loop by which constitutive activation of apelin signalling should participate in the growth of colon adenocarcinomas. Accordingly, apelin signalling is a promising pharmacological target for the treatment of human colon adenomas and adenocarcinomas.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Apoptosis; Colon cancer; G protein-coupled receptors; Signalisation; Tumour growth

Mesh:

Substances:

Year:  2013        PMID: 24316062     DOI: 10.1016/j.ejca.2013.11.017

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  30 in total

1.  Apelin modulates pathological remodeling of lymphatic endothelium after myocardial infarction.

Authors:  Florence Tatin; Edith Renaud-Gabardos; Anne-Claire Godet; Fransky Hantelys; Francoise Pujol; Florent Morfoisse; Denis Calise; Fanny Viars; Philippe Valet; Bernard Masri; Anne-Catherine Prats; Barbara Garmy-Susini
Journal:  JCI Insight       Date:  2017-06-15

2.  Protamine is an antagonist of apelin receptor, and its activity is reversed by heparin.

Authors:  Sophie Le Gonidec; Carline Chaves-Almagro; Yushi Bai; Hye Jin Kang; Allyson Smith; Estelle Wanecq; Xi-Ping Huang; Hervé Prats; Bernard Knibiehler; Bryan L Roth; Larry S Barak; Marc G Caron; Philippe Valet; Yves Audigier; Bernard Masri
Journal:  FASEB J       Date:  2017-02-27       Impact factor: 5.191

3.  Inhibition of the apelin/apelin receptor axis decreases cholangiocarcinoma growth.

Authors:  Chad Hall; Laurent Ehrlich; Julie Venter; April O'Brien; Tori White; Tianhao Zhou; Tien Dang; Fanyin Meng; Pietro Invernizzi; Francesca Bernuzzi; Gianfranco Alpini; Terry C Lairmore; Shannon Glaser
Journal:  Cancer Lett       Date:  2016-11-26       Impact factor: 8.679

4.  Multifunctional APJ Pathway Promotes Ovarian Cancer Progression and Metastasis.

Authors:  Deepika Neelakantan; Samrita Dogra; Bharat Devapatla; Pharavee Jaiprasart; Marie Claire Mukashyaka; Ralf Janknecht; Shailendra Kumar Dhar Dwivedi; Resham Bhattacharya; Sanam Husain; Kai Ding; Sukyung Woo
Journal:  Mol Cancer Res       Date:  2019-03-11       Impact factor: 5.852

Review 5.  The apelin receptor: physiology, pathology, cell signalling, and ligand modulation of a peptide-activated class A GPCR.

Authors:  Nigel A Chapman; Denis J Dupré; Jan K Rainey
Journal:  Biochem Cell Biol       Date:  2014-08-20       Impact factor: 3.626

Review 6.  Apelinergic System Structure and Function.

Authors:  Kyungsoo Shin; Calem Kenward; Jan K Rainey
Journal:  Compr Physiol       Date:  2017-12-12       Impact factor: 9.090

7.  Chronic apelin treatment improves hepatic lipid metabolism in obese and insulin-resistant mice by an indirect mechanism.

Authors:  Chantal Bertrand; Jean-Philippe Pradère; Nancy Geoffre; Simon Deleruyelle; Bernard Masri; Jean Personnaz; Sophie Le Gonidec; Aurélie Batut; Katie Louche; Cédric Moro; Philippe Valet; Isabelle Castan-Laurell
Journal:  Endocrine       Date:  2018-02-01       Impact factor: 3.633

8.  Therapeutic Benefit and Gene Network Regulation by Combined Gene Transfer of Apelin, FGF2, and SERCA2a into Ischemic Heart.

Authors:  Edith Renaud-Gabardos; Florence Tatin; Fransky Hantelys; Benoît Lebas; Denis Calise; Oksana Kunduzova; Bernard Masri; Françoise Pujol; Pierre Sicard; Philippe Valet; Jérôme Roncalli; Xavier Chaufour; Barbara Garmy-Susini; Angelo Parini; Anne-Catherine Prats
Journal:  Mol Ther       Date:  2017-11-16       Impact factor: 11.454

9.  A Preliminary Study of Serum Apelin Levels in Patients with Head and Neck Cancer.

Authors:  Meryem Aktan; Hilal Kiziltunc Ozmen
Journal:  Eurasian J Med       Date:  2019-02

10.  Apelin abrogates the stimulatory effects of 17β-estradiol and insulin-like growth factor-1 on proliferation of epithelial and granulosa ovarian cancer cell lines via crosstalk between APLNR and ERα/IGF1R.

Authors:  Marta Hoffmann; Justyna Gogola; Anna Ptak
Journal:  Mol Biol Rep       Date:  2019-09-20       Impact factor: 2.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.